Next Article in Journal
What is the Burden of Axillary Disease after Neoadjuvant Therapy in Women with Locally Advanced Breast Cancer?
Previous Article in Journal
Corrigendum: A First Look at Participation Rates in Cervical Cancer Screening Programs in Canada
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 20
Issue 2
10.3747/co.20.1217
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Analysis of Intraprostatic Therapeutic Effects in Prostate Cancer Patients Using [11C]-Choline pet/ct after External-Beam Radiation Therapy

by
J. Amanie
1,*,
H.S. Jans
2,
M. Wuest
3,
N. Pervez
1,
A. Murtha
1,
N. Usmani
1,
D. Yee
1,
R. Pearcey
1,
B. Danielson
1,
S. Patel
1,
R. Macewan
3,
C. Field
2,
D. Robinson
2,
J. Wilson
3,
D. Lewis
1,
M. Parliament
1 and
A.J.B. McEwan
2
1
Division of Radiation Oncology, Department of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, AB, Canada
2
Division of Medical Physics Division of Oncologic Imaging, Department of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, AB, Canada
3
Division of Oncologic Imaging, Department of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, AB, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2013, 20(2), 104-110; https://doi.org/10.3747/co.20.1217
Submission received: 6 March 2013 / Revised: 10 March 2013 / Accepted: 13 March 2013 / Published: 1 April 2013

Abstract

Purpose: The objective of the present study was to analyze, with relatively high sensitivity and specificity, uptake properties of [11C]-choline in prostate cancer patients by means of positron-emission tomography (pet)/computed tomography (ct) imaging using objectively defined pet parameters to test for statistically significant changes before, during, and after external-beam radiation therapy (ebrt) and to identify the time points at which the changes occur. Methods: The study enrolled 11 patients with intermediate-risk prostate cancer treated with ebrt, who were followed for up to 12 months after ebrt. The [11C]-choline pet scans were performed before treatment (baseline); at weeks 4 and 8 of ebrt; and at 1, 2, 3, 6, and 12 months after ebrt. Results: Analysis of [11C]-choline uptake in prostate tissue before treatment resulted in a maximum standardized uptake value (suvmax) of 4.0 ± 0.4 (n = 11) at 40 minutes after injection. During week 8 of ebrt, the suvmax declined to 2.9 ± 0.1 (n = 10, p < 0.05). At 2 and 12 months after ebrt, suvmax values were 2.3 ± 0.3 (n = 10, p < 0.01) and 2.2 ± 0.2 (n = 11, p < 0.001) respectively, indicating that, after ebrt, maximum radiotracer uptake in the prostate was significantly reduced. Similar effects were observed when analyzing the tumour:muscle ratio (tmr). The tmr declined from 7.4 ± 0.6 (n = 11) before ebrtto 6.1 ± 0.4 (n = 11, nonsignificant) during week 8 of ebrt, to 5.6 ± 0.03 (n = 11, p < 0.05) at 2 months after ebrt, and to 4.4 ± 0.4 (n = 11, p < 0.001) at 12 months after ebrt. Conclusions: Our study demonstrated that intraprostatic [11C]-choline uptake in the 11 analyzed prostate cancer patients significantly declined during and after ebrt. The pet parameters SUVmax and tmr also declined significantly. These effects can be detected during radiation therapy and up to 1 year after therapy. The prognostic value of these early and statistically significant changes in intraprostatic [11C]-choline pet avidity during and after ebrt are not yet established. Future studies are indicated to correlate changes in [11C]-choline uptake parameters with long-term biochemical recurrence to further evaluate [11C]-choline pet changes as a possible, but currently unproven, biomarker of response.
Keywords: external-beam radiation therapy; ebrt; positron-emission tomography; pet; [11C]-choline external-beam radiation therapy; ebrt; positron-emission tomography; pet; [11C]-choline

Share and Cite

MDPI and ACS Style

Amanie, J.; Jans, H.S.; Wuest, M.; Pervez, N.; Murtha, A.; Usmani, N.; Yee, D.; Pearcey, R.; Danielson, B.; Patel, S.; et al. Analysis of Intraprostatic Therapeutic Effects in Prostate Cancer Patients Using [11C]-Choline pet/ct after External-Beam Radiation Therapy. Curr. Oncol. 2013, 20, 104-110. https://doi.org/10.3747/co.20.1217

AMA Style

Amanie J, Jans HS, Wuest M, Pervez N, Murtha A, Usmani N, Yee D, Pearcey R, Danielson B, Patel S, et al. Analysis of Intraprostatic Therapeutic Effects in Prostate Cancer Patients Using [11C]-Choline pet/ct after External-Beam Radiation Therapy. Current Oncology. 2013; 20(2):104-110. https://doi.org/10.3747/co.20.1217

Chicago/Turabian Style

Amanie, J., H.S. Jans, M. Wuest, N. Pervez, A. Murtha, N. Usmani, D. Yee, R. Pearcey, B. Danielson, S. Patel, and et al. 2013. "Analysis of Intraprostatic Therapeutic Effects in Prostate Cancer Patients Using [11C]-Choline pet/ct after External-Beam Radiation Therapy" Current Oncology 20, no. 2: 104-110. https://doi.org/10.3747/co.20.1217

APA Style

Amanie, J., Jans, H. S., Wuest, M., Pervez, N., Murtha, A., Usmani, N., Yee, D., Pearcey, R., Danielson, B., Patel, S., Macewan, R., Field, C., Robinson, D., Wilson, J., Lewis, D., Parliament, M., & McEwan, A. J. B. (2013). Analysis of Intraprostatic Therapeutic Effects in Prostate Cancer Patients Using [11C]-Choline pet/ct after External-Beam Radiation Therapy. Current Oncology, 20(2), 104-110. https://doi.org/10.3747/co.20.1217

Article Metrics

Back to TopTop